-
2025 CASH丨Professor Jun Shi: Advances in Lentiviral Vector Gene Therapy for Thalassemia
From January 3–5, 2025, the 5th Annual Meeting of Chinese Alliance for Societies of Hematology (CASH) was held in Tianjin under the theme “Comprehensive Hematology, Comprehensive Health, and Comprehensive Well-being.” The event gathered leading experts from China and abroad to discuss the latest advancements and future trends in hematology. Professor Jun Shi, Deputy Director of…
-
World’s First! Fatal Cases of Orupuche Fever Confirmed
On the 25th, the Brazilian Ministry of Health announced the confirmation of two fatal cases caused by Orupuche fever. The deceased were two women from the inland region of Bahia State, both under the age of 30 and without any other illnesses. These are the first recorded fatalities due to Orupuche fever worldwide.
-
For Advanced HR+/HER2- Breast Cancer Patients with Progression after CDK4/6i Treatment, Should We Choose Endocrine Therapy or ADC?
For advanced HR+/HER2- breast cancer patients with progression after CDK4/6i treatment, would you prefer endocrine therapy or ADC (antibody-drug conjugate) treatment? In the “In-depth Debate” session of the 2024 Breast Cancer Summer Forum – Northern Salon, Dr. Xu Liang from Peking University Cancer Hospital and Dr. Nanlin Li from Xijing Hospital of Air Force Medical…
-
In-Depth Analysis丨Dr. Wei Li & Dr. Shaohua Zhang: First-Line Treatment Options for Patients with Recurrent Metastatic Triple-Negative Breast Cancer
For patients with recurrent metastatic triple-negative breast cancer (TNBC), would you choose “chemotherapy + immunotherapy” or “ADC” for treatment? At the 2024 Breast Cancer Summer Forum·Northern Salon “In-Depth Analysis” session, Dr. Wei Li from Jiangsu Provincial People’s Hospital and Dr. Shaohua Zhang from the Chinese PLA General Hospital presented their respective viewpoints. Dr. Wei Li…
-
In-Depth Analysis丨Dr. Qiang Zhang & Dr. Li Wang: Neoadjuvant Immunotherapy Choices for Triple-Negative Breast Cancer
For neoadjuvant immunotherapy in triple-negative breast cancer (TNBC), do you prefer the “TP-AC” or “TP” regimen? At the 2024 Breast Cancer Summer Forum · Northern Salon’s “Raising Questions and Seeking Answers” session, Dr. Qiang Zhang from Liaoning Cancer Hospital and Dr. Li Wang from Xingtai People’s Hospital presented their viewpoints. Dr. Qiang Zhang favors the…
-
2025 CASH丨Professor Ying Wang: Advances in CAR-T Therapy for Acute Lymphoblastic Leukemia (ALL)
At the 5th Annual Meeting of Chinese Alliance for Societies of Hematology (2025 CASH), Professor Ying Wang from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, presented a detailed summary of the latest research on CAR-T therapy for ALL. Her presentation covered the efficacy and safety of CAR-T therapies targeting…
-
Targeted Therapy in BRCA/PALB2-Mutated ER+/HER2- Breast Cancer: Insights from TBCRC 056
At SABCS 2024, Dr. Erica Mayer presented findings from the TBCRC 056 Phase II trial, which investigated the combination of the PARP inhibitor niraparib and anti-PD-1 therapy dostarlimab in neoadjuvant…
-
New Phase 3 Data on Rilzabrutinib for Immune Thrombocytopenia (ITP) – LUNA 3 Trial
Published in Blood and presented at ASH 2024, the LUNA 3 study evaluates the efficacy and safety of rilzabrutinib, an oral Bruton Tyrosine Kinase Inhibitor (BTKi), in patients with previously…
Connecting Medical Expertise through Media